NicOx financial report highlights preclinical Alzheimer's Drug

"Preclinical studies in mice show HCT 1026 may have potential to reduce beta-amyloid deposits in the brains of Azheimer's patients.  The company has previously reported that HCT 1026 is in phase I trials.